Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis

Pancreas

Volumn 30, Issue 3, 2005, Pages 248-253

  Mikami, Yukio ^a   Takeda, Kazunori ^a   Matsuda, Kazuhisa ^a   Qiu Feng, Huang ^a   Fukuyama, Shoji ^a   Egawa, Shinichi ^a   Sunamura, Makoto ^a   Matsuno, Seiki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Continuous regional arterial infusion of protease inhibitor (CRAI); Nafamostat (FUT 175, 6 amidino 2 naphthyl p guanidino benzoate di methane sulfonate); Pancreatic necrosis; Severe acute pancreatitis; Tissue concentration

Indexed keywords

INTERLEUKIN 6; NAFAMSTAT MESILATE; PROTEINASE INHIBITOR; TRYPSINOGEN ACTIVATION PEPTIDE;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELIAC ARTERY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HISTOLOGY; INTERNAL JUGULAR VEIN; JAPAN; LUNG; MALE; MORTALITY; NONHUMAN; PANCREAS; PANCREAS NECROSIS; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

ANIMALS; CELIAC ARTERY; DISEASE MODELS, ANIMAL; GUANIDINES; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; JUGULAR VEINS; LUNG; MALE; PANCREAS; PANCREATITIS; PROTEASE INHIBITORS; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION;

EID: 15444373680     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000153328.54569.28     Document Type: Article

References (35)

1. Freise J, Melzer P, Horbach L, et al. Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multi-center double-blind study with 50 patients. Z Gastroenterol. 1986;24:200-211.
2. Cavallini G, Tittobello A, Di Francesco V, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy Italian Group. N Engl J Med. 1996;335:919-923.
3. Pederzoli P, Cavallini G, Bassi C, et al. Gabexate mesilate vs. aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study. Int J Pancreatol. 1993;14:117-124.
4. Andriulli A, Leandro G, Perri F, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther. 1998;12:237-245.
5. Baden H, Jordal K, Zachariae F, et al. A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. Acta Chir Scand Suppl. 1967; 378:97-102.
6. Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with Trasylol. Report of a controlled therapeutic trial. BMJ. 1965;2:627-629.
7. Imrie CW, Benjamin IS, Blumgart LH, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg. 1978;65:337-341.
8. Buchler M, Malfertheiner P, Beger HG, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology. 1993;104:1165-1170.
9. Valderrama R, Perez-Mateo M, Estruch J, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992;51:65-70.
10. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987;2:698-700.
11. Chen HM, Chen JC, Chen MF, et al. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000;47:1147-1150.
12. Takeda SK, Matsuno S, Atomi Y, et al. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: results of a cooperative survey in Japan. J Hepatobiliary Pancreat Surg. 2001;8:216-220.
13. Takeda K, Yamauchi J, Matsuno S, et al. Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatology. 2001;1:668-673.
14. Takeda K, Sunamura M, Matsuno S, et al. Role of early continuous regional arterial infusion of protease inhibitor and antibiotic in nonsurgical treatment of acute necrotizing pancreatitis. Digestion. 1999;60 (suppl 1):9-13.
15. Takeda K, Matsuno S, Kakugawa Y, et al. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996;171:394-398.
16. Kakugawa Y, Takeda K, Matsuno S, et al. Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction. Nippon Shokakibyo Gakkai Zasshi. 1990;87:1444-1450.
17. Yamauchi J, Takeda K, Matsuno S, et al. Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs. Pancreatology. 2001;1:662-667.
18. Takagi K, Isaji S. Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model. Pancreas. 2000;21:279-289.
19. Fujii S, Hitomi Y. New synthetic inhibitors of Clr, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661:342-345.
20. Aoyama T, Ino Y, Fujita M, et al. Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in vitro and in vivo experiments. Jpn J Pharmacol. 1984;35:203-227.
21. Iwaki M, Ino Y, Aoyama T, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41:155-162.
22. Aho HJ, Koskensalo SML, Nevalainen TJ. Experimental pancreatitis in the rat: sodium-taurocholate induced acute hemorrhagic pancreatitis. Scand J Gastroenterol. 1980;15:411-416.
23. Marunaka T, Maniwa M, Komatsu S, et al. High-performance liquid chromatographic determination of 6-amidino-2-naphthyl [4-(4,5-dihydro-1H- imidazol-2-yl) amino]benzoate dimethanesulphonate and its metabolites in biological fluids. J Chromatogr. 1988;433:177-186.
24. Hughes CB, el-Din AB, Gaber AO, et al. Calcium channel blockade inhibits release of TNF alpha and improves survival in a rat model of acute pancreatitis. Pancreas. 1996;13:22-28.
25. Kim KH, Lee MG, Kim DG. The cholecystokinin receptor antagonist L-364,718 reduces taurocholate-induced pancreatitis in rats. Int J Pancreatol. 1996;20:205-211.
26. Keck T, Balcom JH, Fernandez-del Castillo CF, et al. Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. Surgery. 2001;130:175-181.
27. Klempnauer J, Settje A. Vascularized pancreas transplantation in the rat - details of the microsurgical techniques, results, and complications. Transpl Int. 1989;2:84-91.
28. Iwaki M, Ozeki M, Aoyama T, et al. Pharmacological studies of FUT-175, nafamostat mesilate. II. Folia Pharmacol Jpn. 1984;84:363-372.
29. Iwaki M, Ino Y, Aoyama T, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41:155-162.
30. Menger MD, Bonkhoff H, Vollmar B. Ischemia-reperfusion-induced pancreatic microvascular injury. An intravital fluorescence microscopic study in rats. Dig Dis Sci. 1996;41:823-830.
31. Bockman DE. Microvasculature of the pancreas. Relation to pancreatitis. Int J Pancreatol. 1992;12:11-21.
32. Buchler M, Malfertheiner P, Beger HG, et al. Role of phospholipase A2 in human acute pancreatitis. Gastroenterology. 1989;97:1521-1526.
33. Inoue K, Hirota M, Ogawa M, et al. Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis. Pancreas. 2003;26:218-223.
34. Tamura K, Manabe T, Tobe T, et al. Effect of synthetic protease inhibitors on superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl radical production by human polymorphonuclear leukocytes. Hepatogastroenterology. 1992;39:59-61.
35. Sugita H, Ishiko T, Ogawa M, et al. FUT-175 inhibits the production of IL-6 and IL-8 in human monocytes. Res Commun Mol Pathol Pharmacol. 1999;103:57-64.